Sponsor pipeline

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. clinical trial pipeline

Get alerts when Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.'s trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

8 trials changed in the last 30 days: 0 stopped, 7 with notable changes, 1 with a minor change only.

  3. Notable

    Sponsor changed: NovaOnco Therapeutics Co., Ltd. to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Phase 1/2 NCT06936527 Registry history

    Updated

  6. Notable

    Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

    Also in this update: Trial status changed: Not Yet Recruiting → Active, Not Recruiting

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Phase 1 NCT07035652 Registry history

    Updated

Show 1 trial with minor changes only
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-13 NCT07872579 Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult Males Phase 1 Not Yet Recruiting
2026-09-25 NCT07840820 Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo Phase 2/3 Not Yet Recruiting

Active trials by phase

Phase 1
7
Phase 1/2
3
Phase 2
7
Phase 2/3
1
Phase 3
4
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT07747090 A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24… Paroxysmal Nocturnal Hemoglobinuria Not Yet Recruiting 2026-08-05
NCT07004075 FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade… Low-grade Glioma Not Yet Recruiting 2025-06-04
NCT05913037 FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related… Neurofibromatosis 1 Active, Not Recruiting 2025-03-06
NCT06569420 Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and… Non-Small Cell Lung Cancer Active, Not Recruiting 2024-08-26
Phase 2/3
NCT07840820 Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo Non-segmental Vitiligo Not Yet Recruiting 2026-09-25
Phase 2
NCT07552012 A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With… Active Non-anterior, Non-infectious Uveitis Recruiting 2026-10-15
NCT07562581 A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC Non-small Cell Lung Caner Recruiting 2026-09-02
NCT05997602 To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients… Langerhans Cell Histiocytosis Recruiting 2025-01-24
NCT06981091 A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2… Non-Cystic Fibrosis Bronchiectasis Active, Not Recruiting 2026-09-25
NCT07750665 FXS6837 for the Treatment for IgAN Patients（Longterm Study） Primary IgAN Not Yet Recruiting 2026-08-06
NCT07502638 FXS6837 for the Treatment of IgAN Patients IgAN Not Yet Recruiting 2026-03-31
NCT06858618 FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms Safety Active, Not Recruiting 2025-03-05
Phase 1/2
NCT06936527 XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic… Colorectal Cancer Enrolling by Invitation 2026-09-25
NCT07024394 Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants… Neurofibromatosis 1 Not Yet Recruiting 2025-06-17
NCT04954001 Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of… Neurofibromatosis 1 Active, Not Recruiting 2024-11-12
Phase 1
NCT07616089 Phase I Study of FXS0683 in the Treatment of Blood Tumors B-Cell Lymphoma Recruiting 2026-10-14
NCT07695779 QT Interval Effects Study of Oral FXS5626 Tablets Evaluation of QTc Interval Recruiting 2026-10-14
NCT06820268 A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies B-cell Lymphoma Recruiting 2026-09-25
NCT07872579 Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult Males Healthy Subjects Not Yet Recruiting 2026-10-13
NCT07035652 The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive… Chronic Obstructive Pulmonary Disease Active, Not Recruiting 2026-09-25
NCT07558200 Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors Solid Tumors Not Yet Recruiting 2026-04-30
NCT07345637 Phase I Study of FXS887 in the Treatment of Solid Tumors Solid Tumor Refractory to Conventional Treatment Not Yet Recruiting 2026-01-16
Not applicable
NCT07657052 A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003… Paroxysmal Nocturnal Hemoglobinuria Enrolling by Invitation 2026-09-25

Disease areas by active trials, top 10 of 11

Acute Myeloid Leukemia (AML) (3) · Leukemia (3) · Lung Cancer (3) · Non-Small Cell Lung Cancer (NSCLC) (3) · Myelodysplastic Syndromes (MDS) (2) · Non-Hodgkin Lymphoma (2) · Acute Lymphoblastic Leukemia (ALL) (1) · Colorectal Cancer (1) · COPD (1) · Glioma (1)

Get alerts when Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free